AbbVie Inc. (ABBV)
Stay Ahead of the Game With AbbVie (ABBV) Q4 Earnings: Wall Street's Insights on Key Metrics
Get a deeper insight into the potential performance of AbbVie (ABBV) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
10 Highest Rated Dividend Kings For Generations Of Income
My top 10 Dividend Kings list prioritizes reliability, dividend safety, and attractive valuation for long-term, generational income. Selection criteria include payout ratios under 70%, strong dividend safety/growth grades, and favorable Quant, SA, and Wall Street ratings. ABM Industries leads with a low 31% payout ratio, 2.5% yield, B- safety/growth, and an A- valuation grade despite a Hold Quant rating.
AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in AbbVie Stock?
Investors need to pay close attention to ABBV stock based on the movements in the options market lately.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Best Dividend Kings: January 2026
Dividend Kings underperformed SPY in 2025, averaging 4.91% total return versus SPY's 17.72%, though 14 Kings outperformed the index. 2026 began strongly for Dividend Kings, up 4.66% through January 23rd, outpacing SPY's 1.07% gain. Nineteen Dividend Kings appear both potentially undervalued and offer long-term annualized expected returns of at least 10%.
ABBV vs. MRK: An Oncology-Immunology Showdown for Investors
ABBV has rebounded after Humira patent cliff, with Skyrizi and Rinvoq driving growth. Rising estimates and a pipeline set to power earnings into 2029 bode well.
AbbVie Call Options Spike 2,599%: Tracking the Big Bet
Unusual market activity is often the first sign that big changes are coming to a stock. Professional traders and large institutions frequently use the options market to place high-conviction bets before major news becomes public.
AbbVie (ABBV) Stock Dips While Market Gains: Key Facts
AbbVie (ABBV) reached $216.75 at the closing of the latest trading day, reflecting a -2.32% change compared to its last close.
AbbVie Inc. (ABBV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AbbVie Inc. (ABBV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AbbVie plans to build out its presence in obesity market
AbbVie said on Wednesday it is seeking to expand its presence in the fast-growing market for obesity treatments, leaning on the weight-loss drug it licensed last year from Danish biotech Gubra.
Wall Street Bulls Look Optimistic About AbbVie (ABBV): Should You Buy?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
